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OBJECTIVES We evaluated the effects of growth hormone (GH) on survival in experimental heart failure (HF).
BACKGROUND Growth hormone has been beneficial in various models of experimental HF. Whether GH
also affects HF progression and survival is not known.
METHODS A total of 119 rats with moderate myocardial infarction were randomized to receive either
GH (3.5 mg/kg every other day) or placebo for 28 days. Treatment was initiated one month
after coronary ligation; the follow-up lasted 13 months. In the surviving animals, Doppler
echocardiography and closed-chest Millar left ventricular (LV) catheterization were per-
formed. Apoptosis, collagen volume fraction, and capillary density in the LV zone remote
from infarction were measured. The early effects of GH on apoptosis were also assessed in a
subgroup of eight infarcted rats, treated as specified earlier and euthanized at one month.
RESULTS Survival rate was 68% in GH-treated rats and 48% in the placebo group (p  0.0377).
Growth hormone had no effect on myocardial architecture, systolic function, and sarcoplas-
matic reticulum calcium ATPase-2 messenger ribonucleic acid. Growth hormone improved
LV relaxation; this was associated with a 50% reduction in collagen volume fraction and a
27% increase in capillary density. Growth hormone reduced the apoptotic index by 50% at
one month and by 33% at 13 months.
CONCLUSIONS Growth hormone prolonged survival of rats with postinfarction HF. This effect was
associated with marked attenuation of cardiomyocyte apoptosis and pathologic interstitial
remodeling in the surviving myocardium and enhanced LV relaxation. (J Am Coll Cardiol
2003;41:2154–63) © 2003 by the American College of Cardiology Foundation
Growth hormone (GH) has gained growing attention in the
past decade as an important regulator of myocardial struc-
ture and function (1). Because of its growth-promoting,
vasodilating, and positive inotropic properties, GH has been
recently proposed as an adjunctive therapy in chronic heart
failure (CHF) (2). Indeed, a number of animal studies have
consistently documented the efficacy of GH and its medi-
ator, insulin-like growth factor-I (IGF-I), in attenuating
left ventricular (LV) remodeling and improving myocardial
energetics and function in experimental myocardial infarc-
tion (MI) (3–5). For reasons not completely understood,
clinical studies of GH administration to patients with CHF
have not provided unequivocal results (2,6–9). However,
the issue of whether GH is capable of affecting heart failure
progression and survival is unsettled.
The present study was designed to evaluate the impact of
four-week GH administration on LV remodeling and
mortality in a rat model of post-MI heart failure (HF).
Because cardiomyocyte loss has been hypothesized to be an
important mechanism of myocardial remodeling, and IGF-I
has previously shown to be endowed with powerful antiapo-
ptotic properties (10–12), we also evaluated the effects of
GH treatment on myocardial apoptosis.
METHODS
All methods described conformed to the “Position of the
American Heart Association on Research Animal Use,” and
the protocol was approved by the Animal Care Committee
of the University Federico II of Naples. Myocardial infarc-
tion was induced according to previously described methods
(3) in male Sprague-Dawley rats (Charles River Italy,
Calco, Lodi, Italy), weighing 150 to 200 g, and anesthetized
with pentobarbital (60 mg/kg intraperitoneal) and orally
intubated. Perioperative mortality rate was approximately
35%. One month after coronary ligation, a total of 119
surviving rats were randomized to receive either GH (58
rats), 3.5 mg/kg/every other day for 4 weeks, or placebo (61
rats). The survival study was designed to last 13 months.
During the treatment period, the cages were inspected daily
for dead animals. A postmortem examination was per-
formed, and the lungs were inspected for gross signs of
consolidation. The lungs and heart were placed in formalin
for subsequent necropsy studies. An additional group of
eight infarcted rats was used to assess the early effects of GH
on cardiomyocyte apoptosis. These animals were treated
with GH (n  4) or placebo (n  4) for four weeks, as
described earlier, and were euthanized one month after start of
treatment. This was done because apoptotic death is known to
vanish with time after MI (12), and its occurrence might have
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been too small to detect potential intergroup differences at 13
months.
Echocardiographic and hemodynamic studies. Trans-
thoracic echocardiograms were performed in all surviving
animals, according to previously described methods (3),
with an electronic system equipped with a 7 or 12 MHz
probe (Agilent Technologies, Palo Alto, California). All
measurements, performed with an off-line analysis system
by one observer who was blind to prior results, were based
on the average of three to six consecutive cardiac cycles.
Within 6 h from the final echocardiogram, rats under-
went closed-chest LV catheterization using a calibrated 2 F
micromanometer-tipped catheter (SPR-407, Millar Inst.
Inc., Houston, Texas), as previously described (3). The
time-constant of LV pressure decay (tau) was calculated by
the variable asymptote method.
Morphometric histology and immunohistochemistry.
Twelve hearts from each group were rapidly excised, gross
examined, immersion fixed in formalin 4%, and embedded
in paraffin (3,13). In each animal the following parameters
were assessed from transverse sections (6 m thick) taken at
similar level, by two observers blind to the treatment groups:
1) percentage of infarcted areas, Mallory’s trichrome, picro-
sirius red (3,13,14); 2) cardiomyocyte diameter, hematoxy-
lin, and eosin (50 fields per animal) (3); 3) collagen volume
fraction (CVF) in myocardial areas remote from infarction,
picrosirius red and collagen I and III immunostaining
(Monosan, Uden, The Netherlands), 40magnification, 50
fields per animal; CVF was expressed as the mean percent-
age of connective tissue areas divided by total tissue area in
the same field (14); 4) capillary density taken as the number
of capillaries per mm2 (staining GSLI) (4); and 5) perivas-
cular collagen. Collagen I and III isoforms were also
detected by SDS-PAGE electrophoresis-Western blot ac-
cording to standard methods (15). Slides were observed with a
Nikon Microphot FXA light microscope equipped with a
polarized set and analysed with Zeiss KS300 software.
Cardiomyocyte apoptosis. Apoptosis was assessed both in
the rats euthanized at one month and in the rats surviving at
13 months. Four independent methods were employed to
assess the prevalence of cardiomyocyte apoptosis: 1) the
terminal deoxynucleotidyltransferase-mediated dUTP nick
end labeling (TUNEL, in situ Cell Death Kit, Roche Diag-
nostic, Basel, Switzerland); 2) hairpin probe with single-base 3
overhangs (in situ oligo ligation technique, Apoptag ISOL kit,
Intergen Co., Serological, Norcross, Georgia, plus
streptavidin-fluorescin, Pierce Laboratories, Rockford, Illinois)
(11); 3) caspase-3 activity detection by immunochemistry
(M30, Roche Diagnostic); and 4) deoxyribonucleic acid
(DNA) laddering by agarose gel electrophoresis, to confirm
that immunohistochemical detection of DNA fragments re-
flected internucleosomal DNA cleavage (12).
Cardiomyocytes were identified by incubation with anti-
alpha-actin monoclonal antibody (1:20, Sigma, Saint Louis,
Missouri) and subsequently with anti-mouse IgG TRITC
(tetramethyl rhodamine isothiocyanate) labeled. All the
nuclei were also stained with DAPI (11,12). Positive and
negative controls were performed as previously described
(12). Myocyte apoptotic nuclei were identified and counted
as previously described (10–12). One hundred high-power
fields (120) were evaluated in each section for a total of
1,500 fields per sample. The number of myocyte nuclei
labeled by terminal deoxynucleotidyl transferase (TdT) or
hairpin probe divided by the numerical density of myocyte
nuclei represents the apoptotic index.
SERCA-2 measures. RNAse protection assay (RPA II kit
Ambion, Austin, Texas) and the solution hybridization
RNAse protection assay were performed according to the
manufacturer’s instructions with 20 g of total ribonucleic
acid (RNA), prepared as previously described (16).
Statistical analysis. All results, except survival, are given as
mean  SEM. Statistical analysis was performed using the
SPSS statistical package (SPSS, version 11.0, Chicago,
Illinois). After testing for normal distribution, comparisons
between the two study groups were performed with the
unpaired two-tailed Student t test. The survival curve for each
treatment was determined using the Kaplan-Meier method.
Comparison of the survival distribution between GH- and
placebo-treated rats was performed by a log-rank test.
In planning the study, sample size calculations were
performed with the intent to detect a 20% difference (such
as 60% vs. 80% for 1-year survival) between treatments
with a two-sided significance level of 0.05 and 80% power.
A value of p  0.05 was statistically considered significant.
RESULTS
There were no significant differences in body weights
between the two study groups at baseline, at end of GH
therapy, and at 13 months. Body weight increments at one
month and at 13 months were 18% and 50% in the placebo
group and 24% and 48% in the GH group, respectively
(Table 1). Infarct sizes of rats that died spontaneously were
slightly higher than those of rats euthanized at 13 months:
30  3% versus 28  2% (dead during the trial) and 27 
2% versus 25  3% (euthanized at 13 months) in GH and
placebo groups, respectively (Table 1). Thus, randomization
resulted in a balanced distribution of infarct sizes in both
groups. No rat died of lung infection.
Abbreviations and Acronyms
CHF  chronic heart failure
CVF  collagen volume fraction
DNA  deoxyribonucleic acid
GH  growth hormone
HF  heart failure
IGF-I  insulin-like growth factor I
LV  left ventricular
MI  myocardial infarction
RNA  ribonucleic acid
SERCA-2  sarcoplasmatic reticulum calcium
ATPase-2
TUNEL  terminal UTP nick end labeling
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The survival curves are depicted in Figure 1. Of the 119
rats entered into the study, 68 (39 GH-treated and 29 in the
placebo arm) survived at 13 months. Thus, the 13-month
survival rate was 48% in the placebo group and 68% in
GH-treated rats (p  0.0377 with log-rank test). The
beneficial effect of GH treatment on survival was also
supported by the increase in the mean survival time from
277 days in the placebo group to 323 days in the GH group.
Table 1. Animal Characteristics, Morphometric Histology, and SERCA-2 Myocardial Levels
MI-Placebo MI-GH
Body weightBASELINE, g 311  12 (n  61) 309  15 (n  58)
Body weight4 weeks, g 367  13 (n  61) 384  15 (n  58)
Body weight13 months, g 467  19 (n  29) 460  24 (n  39)
LV wet weight, g 1.32  0.09 (n  29) 1.23  0.11 (n  39)
LV wet/body weight, mg/g 2.79  0.20 (n  29) 2.80  0.32 (n  39)
Infarct size, % 27  3 (n  61) 28  3 (n  58)
Collagen volume fraction, % 4.42  1.9 (n  12) 2.22  0.47* (n  12)
Capillary density, n/mm2 983  160 (n  12) 1247  183* (n  12)
Oxygen diffusion distance, m 16.0  1 (n  12) 14.1  1.1 (n  12)
Perivascular collagen ratio 1.5  0.2 (n  12) 1.4  0.2 (n  12)
SERCA-2, pg/g RNA 1.004  0.05 (n  7) 1.075  0.02 (n  7)
Values are mean  SE. *p  0.05 vs. MI-placebo group.
n  number of animals studied; GH  growth hormone; LV  left ventricular; MI  myocardial infarction; RNA 
ribonucleic acid; SERCA  sarcoplasmic reticulum calcium ATPase.
Figure 1. Kaplan-Meier curves in rats with myocardial infarction treated with placebo or growth hormone (GH). Thirteen-month mean survival time was
267 and 323 days in placebo and GH-treated rats, respectively.
2156 Cittadini et al. JACC Vol. 41, No. 12, 2003
GH and Survival in HF June 18, 2003:2154–63
Assessment of LV function in vivo. Echocardiography
was performed in all surviving rats. However, the data of
only 58 animals were included in the analysis (24 placebo-
treated and 34 GH-treated rats). In the remaining 10 rats,
the recording was not of optimal quality. Similarly, the LV
hemodynamic study was performed in 13 placebo-treated
and 15 GH-treated rats. No significant differences were found
as to LV architecture and systolic function between the two
study groups. There was a tendency toward a reduction of
end-diastolic pressure and posterior wall diastolic load index in
the active treatment group compared with placebo. The time
constant of LV relaxation was shortened by 20% in the
GH-treated rats compared with placebo (p 0.05), indicating
enhanced LV relaxation (Tables 2 and 3).
SERCA-2 myocardial expression. The two infarcted
groups displayed a significant downregulation of myocardial
SERCA-2 mRNA expression (26%) when compared
with an age-matched control group (1.359  0.03 pg/g
RNA), measured by a solution hybridization assay. How-
ever, no significant differences in SERCA-2 transcript levels
were found between the two study groups (Table 1).
Morphometric histology and immunohistochemistry.
Morphometric histology showed no differences in myocyte
diameter between the two groups (22 3 in placebo-treated
vs. 25  5 m in GH-treated animals, p  NS). Sirius red
staining showed a 50% reduction of CVF in GH-treated
versus untreated rats. Perivascular collagen ratio did not
differ significantly between the two groups. Capillary den-
sity increased by 27% in rats receiving GH. Accordingly,
oxygen diffusion distance decreased significantly when com-
pared with controls (14.1  0.4 vs. 16.1  0.5 m in GH
and control group, respectively; p  0.01). Collagen phe-
notype differed between the infarcted animals: the collagen
I/III ratio was approximately 30% lower in the GH-treated
animals than in the placebo group (5.4  0.9 vs. 7.7  1.2;
p  0.01). Also, the histopathologic appearance of collagen
fibers differed in the two study groups. Specifically, in both
the infarcted and noninfarcted areas, the GH-treated group
displayed better preservation of the collagen framework,
with more uniform deposition of collagen I fibers and a
reduction of the typical disarray exhibited by the placebo
infarcted group. Figures 2 and 3 depict representative
photographs from the two study groups.
Apoptosis. The extent of apoptosis did not differ when
measured by TdT or hairpin probe (Figs. 4 to 6), as
previously reported (11). At 13 months, the apoptotic index
was reduced by 33% in the GH-treated rats (20 and 22
cardiomyocyte nuclei/106) compared with the placebo group





Anterior wall diastole, mm 1.20  0.06 1.18  0.07
Anterior wall thickening, % 42  6 36  7
Posterior wall diastole, mm 1.31  0.07 1.42  0.08
Posterior wall thickening, % 67  8 58  10
LV diastolic diameter, mm 8.03  0.32 8.53  0.29
LV systolic diameter, mm 5.3  0.3 5.5  0.28
LV diastolic/body weight, cm/kg 1.72  0.1 1.85  0.14
LV systolic/body weight, cm/kg 1.13  0.09 1.19  0.1
Relative wall thickness 0.33  0.02 0.33  0.02
LV fractional shortening, % 34  4 35  3
Heart rate, beats/min 239  22 249  10
Stroke volume, ml 0.40  0.05 0.45  0.04
Stroke volume/body weight, ml/kg 0.86  0.1 0.99  0.1
Cardiac output, ml/min 97  13 113  19
Cardiac output/body weight, ml/min/kg 204  35 246  28
All data are mean  SE.
Abbreviations as in Table 1.





LV systolic pressure, mm Hg 104  4 110  7
Mean aortic blood pressure, mm Hg 86  3 92  5
LV end-diastolic pressure, mm Hg 11  2 8  2
Peak positive dP/dt, mm Hg/s 3884  444 4255  945
Peak negative dP/dt, mm Hg/s 2317  252 2640  390
Systemic vascular resistance, mm Hg/ml/min/kg 0.42  0.02 0.37  0.03
Posterior wall systolic load index, kdynes/cm2 118  10 126  13
Posterior wall diastolic load index, kdynes/cm2 26  4 19  4
tau, ms 30  2 24  2*
All data are mean  SE; tau  time constant of LV pressure decay; *p  0.05 vs. MI-placebo group.
Abbreviations as in Figure 1.
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(30 and 33 cardiomyocyte nuclei/106), as measured by
TUNEL and hairpin assay, respectively, p  0.069. In the
subgroup of rats euthanized at one month (n 8), there was
a 50% reduction of the apoptotic index in the GH compared
with the placebo group. The TUNEL apoptotic index was
40 and 45 cardiomyocyte nuclei/106 versus 80 and 82
cardiomyocyte nuclei/106, as measured by TUNEL and
hairpin assay, respectively (p  0.001). Caspase activity was
Figure 2. Collagen content and morphology in remote zones from infarction in placebo (left column) and growth hormone (GH)-treated rats (right
column), picrosirius red staining. In the placebo group (A), collagen fibers (in red) appear shorter and thicker than in the GH group (B). Compared with
panel D, panel C exhibits a marked deposition of collagen fibers that encapsulate cardiomyocytes and fill the interstitial gaps. Panels E and F show collagen
I antibody stain in the placebo and GH groups, respectively. In panels G and H collagen I appears red-yellowish, whereas collagen III appears green under
polarized light. Collagen III is substantially reduced in panel G (placebo) compared with panel H (GH). Collagen I is the major component of thick and
short collagen fibers in panel G and of long and thin fibers in panel H, where also a weak collagen III network can be appreciated. Bar  20 m.
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found to co-localize with TUNEL-positive cardiomyocytes,
with 95% of TUNEL-positive nuclei that were also anti-
cleaved caspase-3 positive (Fig. 5). The typical DNA
laddering was apparent in all study groups, confirming the
presence of mono-oligonucleosomes cleavage of genomic
DNA in the observed TUNEL/hairpin-labeled cardiomy-
ocytes (not shown).
DISCUSSION
The present study demonstrates that GH prolongs survival
in a rat model of post-MI HF, and that this effect is
associated with marked attenuation of interstitial fibrosis
and cardiomyocyte apoptosis.
Current study. The most striking difference between the
two study groups was the attenuation of interstitial remod-
eling and cardiomyocyte apoptosis in the non infarcted
myocardium of GH-treated rats. Cardiac fibrosis is re-
garded as one of the major biological determinants of poor
prognosis in HF, insofar as it is strongly associated with
severe arrhythmias, diastolic dysfunction and progression of
chronic heart failure (CHF), and sudden death.
In the current study, a broad spectrum of structural
abnormalities of the extracellular matrix was improved by
GH treatment. Specifically, there was a 50% decrease in
CVF, whereas capillary density was significantly increased.
Growth hormone lowered the collagen I/III ratio, which is
usually increased in animal models of CHF, contributing to
the elevation of operating chamber stiffness (15). The
changes induced by GH in the nonmyocyte compartment
were associated with enhanced LV relaxation. It is a
well-established concept that relaxation abnormalities occur
in ischemic heart disease because of multiple defects, in-
cluding inhibition of Ca2 uptake by the SR, impaired
detachment of force-generating sites between actin and
myosin, nonuniformity, and interstitial fibrosis (17). In the
current study, the enhanced relaxation found in the GH-
treated group appears to depend on the reduced interstitial
fibrosis rather than improvement of SERCA-2, which was
previously reported in post-MI HF following short-term
GH administration (4).
As to the mechanisms by which GH attenuated fibrosis
in our model, one possibility is that GH acts directly by
reducing collagen synthesis or by increasing its breakdown.
This interpretation is unlikely because GH is a powerful
wound-healing stimulator and activates fibroblasts in vitro
(1,18). Another possibility is that GH, by improving he-
modynamics and attenuating LV wall stress, reduces the
accumulation of extracellular matrix proteins in the inter-
stitial space. This interpretation is equally unlikely, given
the similarity of the hemodynamic profile exhibited by the
two study groups. A third possibility is that the well-known
antiapoptotic properties of the GH/IGF-I system (10–12)
may have limited the ongoing cell loss that occurs during
pathologic remodeling. Although apoptosis per se does not
induce fibrosis, it leaves myocardial defects that may become
Figure 3. Collagen morphology in infarcted areas from placebo (left) and growth hormone (GH)-treated rats (right). Panels A and B depict picrosirius
red staining observed under white light. Note that the placebo group (A and C) exhibits disarrayed collagen deposition, whereas in GH group (B and D)
the collagen network appears better preserved, with collagen scar fibers organized in parallel bundles. In both groups, scars are mainly made of collagen I
fibers, as shown under polarized light microphotographs. Bar  20 m.
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Figure 4. Prevalence of cardiomyocyte apoptosis in the two study groups as measured by terminal deoxynucleotidyl transferase (TdT) and hairpin assays. The apoptotic index was assessed as described in











Figure 5. Cardiomyocyte apoptosis in remote areas from infarction observed under fluorescent light. Panels A, B, and F depict representative triple staining
obtained in the same microscopic fields from a growth hormone (GH)-treated rat euthanized at one month. Panel A shows cardiomyocyte and
non-cardiomyocyte nuclei stained with DAPI. Panel B depicts cardiomyocyte immunostained with anti-sarcomeric actin. Panels C to F depict detection
of terminal UTP nick end labeling (TUNEL)-positive cardiomyocyte nuclei. Panels C and D are representative images from placebo and GH group,
respectively, after the 13-month observation period. Panels E and F are representative images from placebo and GH rats, respectively, euthanized at one
month. Note the higher percentage of positive nuclei in the placebo-treated animals. Panel G: Immunostaining for activated caspase-3 antibody. Panel
H: Double-exposure photomicrograph of dual labeled cardiomyocytes for activated caspase-3 (red signal) and TUNEL. Note the co-localization of caspase
activity and TUNEL-positivity in the same cardiomyocyte. Overlapped signals result in yellow fluorescence. Bars  20 m.
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filled with interstitial fluid arising from myocardial edema,
which subsequently leads to accumulation of fibrous tissue.
In other words, GH might have the potential to prevent
rather than reduce fibrosis (18). The marked reduction of
the apoptotic index exhibited by GH-treated animals
strongly supports this hypothesis. Our findings of decreased
apoptotic death following GH/IGF-I activation are congru-
ent with recent data obtained both in animals treated with
exogenous GH or IGF-I and in transgenic mice overex-
pressing IGF-I (10–12).
Comparison with previous work. The magnitude of sur-
vival benefit in the current study (20%) was lower than that
obtained with high doses of angiotensin-converting enzyme
inhibitors, which ranged from 25% to 40% (14,19). Note-
worthy, in our study the two survival curves began to clearly
diverge around day 200 and continued to do so thereafter,
showing the largest separation during the last weeks of
observation. This implies that GH in some way altered the
underlying mechanisms of the disease progression. In con-
trast, the survival curves, observed when angiotensin-
converting enzyme inhibitors or beta-blocking agents were
used in animal or human CHF (20), start to diverge at an
early stage, but then become parallel. This suggests atten-
uation or loss of effectiveness of neurohormonal antagonism
as heart failure progresses.
Previous studies addressed the effects of GH on the
nonmyocyte compartment (21,22). High-dose GH admin-
istration to normal rats for 80 days slightly decreased CVF,
without modifying the collagen I/III ratio (22), in line with
earlier observations in normal and failing rats (3,4). In the
aggregate, the data available suggest that only long-term
GH excess, such as that occurring in acromegaly, induces
fibrosis with histopathologic signs of inflammation of the
myocardial interstitium (1), whereas in the short term GH
does not stimulate myocardial fibrosis, as shown by animal
and human studies (23).
A very recent study examined the long-term effects of
GH in a rat model of acute MI (24). At variance with the
present study, GH treatment was initiated very early (on the
day of MI). Growth hormone reduced the infarct size and
increased the relative survival rate by 36% at 52 weeks. The
study did not look at the effects of GH on myocardial
histology and LV function. However, the interesting obser-
vation was made that GH downregulated the expression of
Figure 6. Detection of apoptosis in cardiomyocyte nuclei of left ventricular area remote from infarction by hairpin probe. The oligo was recognized by a
streptavidin fluorescin conjugate. Panels A and B are representative images from the placebo and the growth hormone (GH) group, respectively, after the
13-month observation period. Panels C and D are representative images from placebo and GH rats euthanized soon after the active treatment period (1
month). Bar  20 m.
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fetal genes regarded as markers of CHF progression, such as
the atrial natriuretic factor, alpha-smooth muscle actin, and
beta-myosin heavy chain. In agreement with our data,
SERCA-2 was unaffected by GH. Particularly interesting
was the observation that GH prevented the overexpression
of extracellular matrix genes, such as collagen I, collagen III,
and fibronectin. The data are in close agreement with the
current study and complement our observations based on
direct examination of myocardial tissue structure.
Clinical implications. Whereas GH and IGF-I have almost
invariably been beneficial in experimental heart failure, previ-
ous studies in CHF have provided inconsistent results (2,6–9).
The most likely explanation for this discrepancy resides in the
fact that patients with CHF present with a wide spectrum of
GH/IGF-I conditions, encompassing GH deficiency and
severe GH resistance (25). In the former, GH administration
only acts as a replacement therapy, whereas in the latter GH is
unable to cause sufficient generation of its effector IGF-I.
Indeed, when the authors of the largest clinical study of GH in
CHF (6) re-analyzed their data by discriminating those pa-
tients who did not respond to GH administration with
substantial IGF-I production, they could demonstrate signifi-
cant effects of GH on LV function (9).
As discussed in a recent review (26), the perfect surrogate
end point in CHF does not exist yet, and mortality is still
regarded as the standard for assessing the efficacy of a new
therapeutic strategy. In the present study, GH did not
improve LV systolic function despite its effect to prolong
survival. This finding bears several implications. First, it
supports the stance that questions the validity of hemody-
namic changes as surrogate end points of mortality. Second,
the data point to the importance of structural changes in the
myocardium and apoptosis, events that are not usually
addressed in clinical studies. Ultimately, the effects of GH
and IGF-I on the interstitium and apoptosis here reported
are among those most consistently found in previous stud-
ies, and this encourages testing of the hypothesis that GH
may affect the progression of clinical CHF.
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